Neurology Consultant spoke with the SELECT trial national principal investigator and lead author Amrou Sarraj, MD, whose trial shed light on how the use of imaging modalities can be optimized following the onset of acute ischemic stroke in...
Neurology Consultant spoke with the SELECT trial national principal investigator and lead author Amrou Sarraj, MD, whose trial shed light on how the use of imaging modalities can be optimized following the onset of acute ischemic stroke in...
The American Heart Association/American Stroke Association’s Stroke Council Leadership has released temporary emergency guidance on stroke care during the COVID-19 pandemic.
The American Heart Association/American Stroke Association’s Stroke Council Leadership has released temporary emergency guidance on stroke care during the COVID-19 pandemic.
It is sometimes challenging to capture multiple sclerosis disease activity and, therefore, to track the efficacy of interventions. Do you think current measures are relevant for assessing intervention outcomes?
It is sometimes challenging to capture multiple sclerosis disease activity and, therefore, to track the efficacy of interventions. Do you think current measures are relevant for assessing intervention outcomes?
Investigators of the RESTORE BRAIN study determined whether a selective GABAA α5 receptor antagonist is a safe and effective therapy for patients with ischemic stroke.
Investigators of the RESTORE BRAIN study determined whether a selective GABAA α5 receptor antagonist is a safe and effective therapy for patients with ischemic stroke.
Do you know which vaccine is NOT recommended for patients with multiple sclerosis who are initiating immunotherapy? Test your knowledge with our latest pop quiz!
Do you know which vaccine is NOT recommended for patients with multiple sclerosis who are initiating immunotherapy? Test your knowledge with our latest pop quiz!
Researchers investigated the entire spectrum of myelin oligodendrocyte glycoprotein antibody-associated syndromes in children. The frequency, distribution, and treatment response of the syndromes were uncovered.
Researchers investigated the entire spectrum of myelin oligodendrocyte glycoprotein antibody-associated syndromes in children. The frequency, distribution, and treatment response of the syndromes were uncovered.
After identifying 3 neuroprotective drugs acting on different axonal pathobiologies, the researchers assessed each drug’s efficacy on percentage brain volume change among patients with secondary progressive multiple sclerosis. Their results...
After identifying 3 neuroprotective drugs acting on different axonal pathobiologies, the researchers assessed each drug’s efficacy on percentage brain volume change among patients with secondary progressive multiple sclerosis. Their results...
Can apolipoprotein CIII plasma concentration predict whether a patient with coronary artery disease is at greater risk for experiencing ischemic stroke or a transient ischemic attack? Here are the results of the latest study.
Can apolipoprotein CIII plasma concentration predict whether a patient with coronary artery disease is at greater risk for experiencing ischemic stroke or a transient ischemic attack? Here are the results of the latest study.
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke.
“In aging...
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke.
“In aging...
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
To view accreditation information/faculty disclosures for the program, click
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
To view accreditation information/faculty disclosures for the program, click
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
To view accreditation information/faculty disclosures for the program, click